ABSTRACT
Fundamento y objetivo: El propósito del trabajo fue estudiar la tolerabilidad de dos soluciones salinas hipertónicas (SSH) en pacientes con fibrosis quística (FQ).Pacientes y método: Se estudiaron 81 pacientes con FQ (44 varones, edad media 23,63 años). Los pacientes inhalaron 5ml de una SSH al 7%. Los que no la toleraron inhalaron, al menos 24 horas después, 5ml de una SSH al 7% con ácido hialurónico al 0,1%.Resultados: Veintiún pacientes (26%) no toleraron la SSH inmediatamente tras su inhalación. La tos fue la causa más frecuente de no tolerancia. Los mayores de 18 años y los que tenían peor función pulmonar toleraron la SSH peor. El 81% de los pacientes que no toleraron la SSH toleraron bien la SSH con hialurónico. Conclusiones: Bastantes pacientes con FQ no toleran la inhalación de la SSH inmediatamente tras su nebulización. Los mayores de 18 años y los que tienen peor función pulmonar la toleraron peor. El ácido hialurónico añadido a la SSH minimiza los efectos secundarios de ésta (AU)
Background and objective: The aim of our study was to evaluate the tolerance of two inhaled hypertonic saline solutions (HS) in patients with cystic fibrosis. Patients and method: Eighty one cystic fibrosis (CF) patients (44 males; mean age 23.63years) inhaled 5ml of 7% inhaled HS solution and, in those patients who did not tolerate HS, we evaluated the tolerance of a 7% HS (at dose of 5ml) added to 0.1% hyaluronic acid at least twenty-four hours later. Results: Twenty one (26%) patients did not tolerate the HS solution immediately after its inhalation. Cough was the most common symptom. Patients over 18years of age showed worse tolerance to HS than patients younger than 18years of age. Those patients that did not tolerate HS had a worse lung function that the ones that showed good tolerance. Eighty-one percent of patients who did not tolerate the HS alone tolerated well the HS with hyaluronic acid. Conclusions: CF patients cannot tolerate inhaled HS immediately after nebulisation. Patients over 18years and those with worse lung function tolerate HS worst. Hyaluronate acid added to 7% HS solution improves the tolerability (AU)
Subject(s)
Humans , Male , Female , Cystic Fibrosis/drug therapy , Hypertonic Solutions/administration & dosage , Hyaluronic Acid/administration & dosage , Administration, Inhalation , Drug Tolerance , Nasal Mucosa , Mucociliary Clearance/physiologyABSTRACT
BACKGROUND AND OBJECTIVE: The aim of our study was to evaluate the tolerance of two inhaled hypertonic saline solutions (HS) in patients with cystic fibrosis. PATIENTS AND METHOD: Eighty one cystic fibrosis (CF) patients (44 males; mean age 23.63 years) inhaled 5 ml of 7% inhaled HS solution and, in those patients who did not tolerate HS, we evaluated the tolerance of a 7% HS (at dose of 5 ml) added to 0.1% hyaluronic acid at least twenty-four hours later. RESULTS: Twenty one (26%) patients did not tolerate the HS solution immediately after its inhalation. Cough was the most common symptom. Patients over 18 years of age showed worse tolerance to HS than patients younger than 18 years of age. Those patients that did not tolerate HS had a worse lung function that the ones that showed good tolerance. Eighty-one percent of patients who did not tolerate the HS alone tolerated well the HS with hyaluronic acid. CONCLUSIONS: CF patients cannot tolerate inhaled HS immediately after nebulisation. Patients over 18 years and those with worse lung function tolerate HS worst. Hyaluronate acid added to 7% HS solution improves the tolerability.
